Barclays PLC Has $79,000 Stock Holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Barclays PLC cut its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 89.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,767 shares of the company's stock after selling 777,507 shares during the period. Barclays PLC owned 0.08% of Karyopharm Therapeutics worth $79,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in KPTI. Geode Capital Management LLC increased its stake in shares of Karyopharm Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company's stock valued at $1,125,000 after purchasing an additional 43,856 shares during the period. FMR LLC increased its position in Karyopharm Therapeutics by 26.1% in the 3rd quarter. FMR LLC now owns 369,723 shares of the company's stock valued at $307,000 after acquiring an additional 76,510 shares during the period. GSA Capital Partners LLP raised its stake in Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock valued at $1,474,000 after acquiring an additional 792,283 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company's stock worth $182,000 after acquiring an additional 56,613 shares during the period. Finally, Point72 DIFC Ltd bought a new position in shares of Karyopharm Therapeutics in the second quarter worth $31,000. 66.44% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on KPTI. Piper Sandler lifted their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an "overweight" rating in a research note on Wednesday, November 6th. StockNews.com downgraded shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 22nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Karyopharm Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $5.00.

Karyopharm Therapeutics Trading Up 1.7 %

NASDAQ:KPTI traded up $0.01 during mid-day trading on Friday, reaching $0.70. 433,181 shares of the stock were exchanged, compared to its average volume of 883,790. The business has a fifty day moving average price of $0.73 and a 200 day moving average price of $0.80. Karyopharm Therapeutics Inc. has a 1-year low of $0.58 and a 1-year high of $1.95. The firm has a market capitalization of $88.32 million, a PE ratio of -0.61 and a beta of 0.07.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. The business had revenue of $38.78 million during the quarter, compared to analyst estimates of $37.86 million. During the same period in the prior year, the firm earned ($0.30) EPS. On average, sell-side analysts forecast that Karyopharm Therapeutics Inc. will post -0.96 earnings per share for the current year.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).